1.405
전일 마감가:
$1.40
열려 있는:
$1.43
하루 거래량:
2.60M
Relative Volume:
1.10
시가총액:
$121.97M
수익:
-
순이익/손실:
$-37.34M
주가수익비율:
-1.0331
EPS:
-1.36
순현금흐름:
$-36.91M
1주 성능:
+8.53%
1개월 성능:
+26.13%
6개월 성능:
+14.75%
1년 성능:
-4.11%
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
SLS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SLS
Sellas Life Sciences Group Inc
|
1.405 | 121.97M | 0 | -37.34M | -36.91M | -1.36 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
494.55 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
608.93 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
618.41 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
254.13 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
250.53 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
2018-11-01 | 개시 | Oppenheimer | Outperform |
2018-04-02 | 개시 | H.C. Wainwright | Buy |
2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SELLAS Unveils Breakthrough Preclinical Data Highlighting - GlobeNewswire
Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan
SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com
The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News
Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX
SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World
SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting - Nasdaq
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire
Clinical Trial Breakthrough: SELLAS Unveils Novel Cancer Drug Results for Hard-to-Treat ASXL1 Mutations - Stock Titan
How did SELLAS Life Sciences Group Inc (SLS) fare last session? - uspostnews.com
Analysts review SELLAS Life Sciences Group Inc’s rating - knoxdaily.com
Loop Capital analysts downgrades a Sell rating for Canadian National Railway Co (CNI) - knoxdaily.com
Analysts Are Recommending SELLAS Life Sciences Group Inc (SLS) As A Buy Candidate - Marketing Sentinel
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt
SELLAS reports promising AML treatment trial results - Investing.com
SELLAS posts mid-stage trial win for leukemia drug (SLS:NASDAQ) - Seeking Alpha
Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up - MarketScreener
Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009 - Nasdaq
SELLAS reports promising AML treatment trial results By Investing.com - Investing.com India
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewswire
Breakthrough: New Leukemia Drug Shows 8.8-Month Survival vs 2.5-Month Standard - Stock Titan
Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World
Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha
Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World
Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq
SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView
SELLAS Life Sciences Group Inc. (SLS) reports earnings - Quartz
SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday - Defense World
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register
Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance
SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN
SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire
3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail
SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq
SELLAS reports promising DLBCL treatment trial results - Investing.com
SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq
SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle
SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News
Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex
Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News
SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat
SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):